On August 5, Hinge Health, Inc. rose 5.03% in regular trading, trading at $81.47/share, with turnover of $87.49 million. The rally followed the company's Q2 earnings report released after the close on August 4, with market consensus expecting quarterly revenue of approximately $201 million (up 60.38% year-over-year) and adjusted earnings per share of $0.59 (up 582.69% year-over-year).

The earnings release caps a series of positive developments. The company had previously raised its full-year revenue outlook to $818-$824 million, well above analyst estimates, after strong Q1 results that beat expectations on both revenue and earnings. A recently published study in the Journal of Comparative Effectiveness Research demonstrated that Hinge Health's fall prevention program reduced falls by 37% and emergency visits by 57% among adults aged 65 and older, further validating clinical efficacy. Morgan Stanley raised its price target to $108 from $72 maintaining an Overweight rating, while RBC Capital Markets highlighted a long runway for growth driven by new products including HingeSelect Surgery and margin expansion potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)